365413-06-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 6-AMINO-5-METHOXYNICOTINATE is used as an intermediate in the synthesis of biologically active compounds for various therapeutic applications due to its chemical properties and low toxicity.
Used in Anti-inflammatory Applications:
METHYL 6-AMINO-5-METHOXYNICOTINATE is used as an anti-inflammatory agent for its potential to mitigate inflammation, which is crucial in treating a range of conditions.
Used in Antioxidant Applications:
It is utilized as an antioxidant to combat oxidative stress, which is implicated in numerous diseases and aging processes.
Used in Cardiovascular Disease Treatment:
METHYL 6-AMINO-5-METHOXYNICOTINATE is used as a therapeutic agent in the treatment of cardiovascular diseases, potentially benefiting from its anti-inflammatory and antioxidant properties to protect the heart and blood vessels.
Used in Neurodegenerative Disorder Treatment:
METHYL 6-AMINO-5-METHOXYNICOTINATE is also considered for use in treating neurodegenerative disorders, capitalizing on its potential neuroprotective effects that could slow disease progression or manage symptoms.

Upstream product

• 1214353-70-4 methyl 5-hydroxy-6-nitronicotinate 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 59288-43-6 5-hydroxy-6-nitropyridine-3-carboxylic acid 
• 27828-71-3 5-hydroxynicotinic acid 

Relevant academic research and scientific papers

Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability. In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochemical properties to balance absorption and metabolic stability. Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem. The selected compound series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivatives. The resulting optimized compound, BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties.

Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases

The present invention relates to substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of BET proteins, especially BRD4 proteins and polo-like kinases, especially Plk-1 proteins, of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6, R

N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.